Kolexia
Rosmorduc Olivier Gastro-entérologie
Rosmorduc Olivier
Gastro-entérologie
Hôpital Paul Brousse
Villejuif, France
131 Activités
1 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Carcinome hépatocellulaire Carcinomes Tumeurs du foie Maladies du foie Récidive tumorale locale Cirrhose du foie Stéatose hépatique non alcoolique Cholangiocarcinome Tumeurs des voies biliaires

Collaborateurs

Voir plus
Fartoux Laetitia
Fartoux Laetitia
Clinique Chirurg Alleray Labrouste, Paris, France
Merle Philippe
Merle Philippe
Hôpital La Croix-Rousse, Lyon, France
Scatton Olivier
Scatton Olivier
Hôpital Saint-Antoine, Paris, France
Bronowicki Jean Pierre
Bronowicki Jean Pierre
Hôpital Brabois, Vandoeuvre-lès-Nancy, France

Industries

Voir plus
Ipsen
8 collaboration(s)
Dernière en 2022
Bayer
8 collaboration(s)
Dernière en 2022
Sirtex Medical Europe GmbH
3 collaboration(s)
Dernière en 2021
MSD
2 collaboration(s)
Dernière en 2022

Dernières activités

Voir plus
An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma: A Randomized, Multi-center Phase III Study of Nivolumab Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma (CheckMate 459: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 459)
Essai Clinique (BMS)   15 mars 2024
RP3 in Combination With 1L or 2L Therapy in Patients With Locally Advanced Unresectable or Metastatic HCC: A Phase 2, Open-label, Multicenter Study Investigating RP3 Oncolytic Immunotherapy in Combination With First- or Second-line Therapy in Patients With Locally Advanced Unresectable or Metastatic Hepatocellular Carcinoma
Essai Clinique (Replimune Inc.)   21 décembre 2023
Immune checkpoints are predominantly co-expressed by clonally expanded CD4 FoxP3 intratumoral T-cells in primary human cancers.
Journal of experimental & clinical cancer research : CR   06 décembre 2023
SAFIR-ABC10: Molecular Targeted Maintenance Therapy Versus Standard of Care in Advanced Biliary Cancer: an International, Randomised, Controlled, Open-label, Platform Phase 3 Trial
Essai Clinique (Taiho Oncology, Inc.)   15 novembre 2023
TERTIO: Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: a Proof of Concept Randomized Phase II Study (TERTIO - Prodige 82)
Essai Clinique (CHU Besançon)   10 novembre 2023
New epidemiologic trends in cholangiocarcinoma.
Clinics and research in hepatology and gastroenterology   04 octobre 2023
Unresectable hepatocellular carcinoma at dawn of immunotherapy era: real-world data from the French prospective CHIEF cohort.
European journal of gastroenterology & hepatology   11 août 2023
Evaluation of the interest to combine a CD4 Th1-inducer cancer vaccine derived from telomerase and atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: a randomized non-comparative phase II study (TERTIO - PRODIGE 82).
BMC cancer   29 juillet 2023
Ta-Len-Tra: Study of the Benefit of Lenvatinib Treatment in Waiting List of Liver Transplantation After TACE Failure in Patients With Hepatocellular Carcinoma (HCC)
Essai Clinique (Eisai)   12 juin 2023
Progressive erythrocytosis under lenvatinib treatment in patients with advanced hepatocellular carcinoma.
Cancer chemotherapy and pharmacology   24 mars 2023